VALIDARSE | REGISTRARSE | ZONA PERSONAL | MAPA WEB
  RSS | Foro | Blog | Buzón de sugerencias | Tu contacto con Roche | Grupos de trabajo
INICIO NOTICIAS REUNIONES Y EVENTOS PRODUCTOS ENLACES SEGURIDAD CLÍNICA JOURNAL REVIEW SERVICE
Actualidad | Comunicados de prensa | Nuevas Indicaciones y Productos | Noticias Sanitarias | Noticias CC.AA | Foro
5 de septiembre 2010
  



Interferón pegilado Alfa-2A, tratamiento que mayor curación ofrece ante la hepatitis C
19 de abril 2010 |
La combinación de interferón pegilado alfa-2a ('Pegasys', de Roche) y Ribavirina ha demostrado en una revisión llevaba a cabo por el grupo Hepatobiliar de la Colaboración Cochrane, ser el tratamiento más adecuado para la hepatitis C (VHC), pues los pacientes en tratamiento con Pegasys tienen un 11% más de posibilidades de alcanzar la curación que los que siguen el otro tratamiento disponible (R.R = 1,11).

  Ver +
APROBADO EN ESPAÑA EL USO DE AVASTIN® MÁS DOCETAXEL COMO TRATAMIENTO DE PRIMERA LÍNEA PARA EL CÁNCER DE MAMA METASTÁSICO
3 de marzo 2010 | Noticias Roche
Esta autorización amplía el potencial combinatorio del antiangiogénico en el segmento de los taxanos.La nueva aprobación permitirá que más pacientes se beneficien del tratamiento con Bevacizumab en primera línea, al poder combinarse con dos de las quimioterapias de uso más frecuente.

  Ver +
FDA Approves ACTEMRA(R) (tocilizumab) For The Treatment Of Moderately To Severely Active Rheumatoid Arthritis
12 de enero 2010 | Health News from Medical News Today
Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved ACTEMRA® (tocilizumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies...

  Ver +
FDA Advisory Committee Recommends Against Approving Tarceva For First-Line Maintenance Use In Advanced Non-Small Cell Lung Cancer
18 de diciembre 2009 | Health News from Medical News Today
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG)(OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one recommending against approval of the daily pill Tarceva® (erlotinib) for first-line maintenance use in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has not progressed (grown or spread) following first-line treatment with platinum-based chemotherapy...

  Ver +
Bevacizumab (Avastin) Could Play An Important Role In Improving The Neurocognitive Function Of Patients With The Most Aggressive Form Of Brain Cancer
24 de septiembre 2009 | Health News from Medical News Today
Roche today announced that an analysis of the phase II BRAIN study of bevacizumab (Avastin®) alone or in combination with irinotecan chemotherapy for the treatment of relapsed or progressive glioblastoma (GBM) demonstrated that in addition to increasing the chance of patients being alive without

  Ver +
FDA Approves Bevacizumab for Treatment of Metastatic Renal Cell Carcinoma
5 de agosto 2009 | Medscape Medical News Headlines
The FDA has approved a new indication for bevacizumab intravenous infusion, allowing its use for the treatment of metastatic renal cell carcinoma. Medscape Medical News

  Ver +
Tarceva Extends Lung Cancer Survival
15 de julio 2009 | Medscape Medical News Headlines
Tarceva improved the survival of patients with advanced lung cancer when used immediately after initial chemotherapy, Roche Holding AG said on Monday. Reuters Health Information

  Ver +
ASC0 2009: RIBBON-1 Trial Confirms Bevacizumab in Breast Cancer
16 de junio 2009 | Medscape Medical News Headlines
A third trial has confirmed that bevacizumab prolongs progression-free survival in patients with metastatic breast cancer, although no improvement in overall survival has yet been shown. Medscape Medical News

  Ver +
Avastin (bevacizumab) Approved By FDA For Treatment Of Aggressive Brain Cancer
10 de mayo 2009 | Health News from Medical News Today
The FDA (Food and Drug Administration, USA) approved Avastin (bevacizumab) for patients with GBM (glioblastoma multiforme) whose cancer carries on progressing after standard therapy. GBM is a rapidly progressing cancer - it invades brain tissue and can may have a significant effect on a patient´s mental abilities and physical activities.

  Ver +
Bevacizumab Approved for Recurrent Glioblastoma
7 de mayo 2009 | Medscape Medical News Headlines
The US Food and Drug Administration has granted accelerated approval for the use of bevacizumab in patients with glioblastoma that has progressed on previous therapy. Medscape Medical News

  Ver +


Encontrados 112 artículos Páginas [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12]


 
VALIDARSE
  REGISTRARSE
Usuario
Contraseña
Calidad Sanitaria, Seguridad de Pacientes o las últimas noticias relacionadas con la Gestión Sanitaria en Roche Instituciones. Si desea acceder a estos servicios regístrese o contacte con su Delegado de zona de Roche.
Septiembre 2010
L M X J V S D
    01020304 05
06 070809 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30      

Próximos eventos:
Congreso europeo de directores de hospitales
Gestión sanitaria
Del 8 al 10 de septiembre

23º Congreso Europeo de Directores de Hospitales
Gestión sanitaria
9 y 10 de julio

Sello de calidad Medicina XXI